Shareholding disclosure

Basilea Pharmaceutica AG

Declared position

24.35%

Threshold

Crossed downwards

Timeline

Published

30.12.2022

Transaction

23.12.2022

Voting rights breakdown

Voting rights acquired8.77%

Voting rights sold24.35%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAMCS00016

Beneficial owner

Basilea Pharmaceutica AG

Declared address

Basilea Pharmaceutica AG, 4051 Basel

Repayment of convertible bonds

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Basilea Pharmaceutica AG

Basilea Pharmaceutica AG, Allschwil30.12.2022TAMCS00016

Disclosure summary

Basilea Pharmaceutica AG disclosed a holding in Basilea Pharmaceutica AG, Allschwil on the disposal side, published by SIX Exchange Regulation on 30.12.2022, at 24.35% of voting rights. Notice category: Single shareholder.

Disclosed position

24.35%

Voting rights sold

Voting rights acquired8.77%

Voting rights sold24.35%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Basilea Pharmaceutica AG disclosed a holding in Basilea Pharmaceutica AG, Allschwil, published on 30.12.2022.

Publication date30.12.2022

Transaction date23.12.2022

Issuing companyBasilea Pharmaceutica AG, Allschwil

Beneficial ownerBasilea Pharmaceutica AG

Declared addressBasilea Pharmaceutica AG, 4051 Basel

CategorySingle shareholder

Voting rights acquired8.77%

Voting rights sold24.35%

Below threshold0%

ExchangeXSWX

Notification IDTAMCS00016

Commercial register

CHE-101.175.068

Registered

Zefix record

Conditions

Repayment of convertible bonds

Source: SIX Exchange Regulation · Publication date: 30.12.2022

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open